KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target?

International Journal of Cancer

Volumn 120, Issue 11, 2007, Pages 2510-2516

  Entz Werle, Natacha ^a   Gaub, Marie Pierre ^a   Lavaux, Thomas ^a   Marcellin, Luc ^b   Metzger, Nadia ^a   Marec Berard, Perrine ^c   Schmitt, Claudine ^d   Brugiere, Laurence ^e   Kalifa, Chantal ^e   Tabone, Marie Dominique ^f   Pacquement, Hélène ^g   Gentet, Philippe ^h   Lutz, Patrick ^a   Oudet, Pierre ^a   Babin, Annie ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CHU NANCY BRABOIS   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g INSTITUT CURIE   (France)

^h TIMONE HOSPITAL   (France)

Author keywords

KIT gene; Osteosarcoma; Pediatric; Target

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; CHROMOSOME 4Q; FEMALE; GENE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIT GENE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PDGFRA GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VEGFR2 GENE;

ADOLESCENT; ADULT; BASE SEQUENCE; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 4; DNA PRIMERS; FEMALE; HUMANS; MALE; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 34247333691     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22593     Document Type: Article

References (37)

1. Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G, Rodeck U. Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 2001;61:2200-6.
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Anderson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
4. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
5. Krystal W, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;8:3319-26.
6. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
7. Tian Q, Frierson HF, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-7.
8. Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 2003;94:486-91.
9. Tamborini E, Bonadiman L, Negri T, Greco A, Staurengo S, Bidoli P, Pastorino U, Pierotti MA, Pilotti S. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004;10:8214-19.
10. Feger F, Ribadeau-Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002;127:110-14.
11. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002;26:486-92.
12. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst (Bethesda) 2002;94:1673-9.
13. Tamborini E, Bonadiman L, Albertini V, Pierotti MA, Pilotti S. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst (Bethesda) 2003;95:1087-8.
14. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
15. Violas P, Kohler R, Mascard E, Bollini G, Kalifa C, Dubousset J. Conservative surgical treatment of osteogenic sarcoma of the limb in children and adolescents [in French]. Rev Chir Orthop Reparatrice Appar Mot 2000;86:675-83.
16. Kalifa C, Guinebretière JM, Gentet JC, Philip T, Dupouy N, Bellon N, Rodary C. Comparison of doxorubicin versus etoposideifosfamide in addition to HDMTX as preoperative chemotherapy in osteosarcoma: a randomized trial by the French Society of Pediatric Oncology. Proc Am Soc Clin Oncol 2002;21:409a (Abstract 1634).
17. Entz-Werle N, Marcellin L, Gaub M-P, Guerin E, Schneider A, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone M-D, Oudet P et al. C-kit analysis and its expression in pediatric osteosarcomas. J Clin Oncol 2005;23:2248-55.
18. Entz-Werle N, Stoetzel C, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Quillet R, Oudet P, Lutz P, et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer 2005;117:349-55.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988;16:1215.
20. Schneider A, Borgnat S, Lang H, Regine O, Lindner V, Kassem M, Saussine C, Oudet P, Jacqumin D, Gaub MP. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 2000;60:4617-22.
21. Alonso ME, Bello MJ, Arjona D, Martinez-Glez V, De Campos JM, Isla A, Kusak E, Vaquera J, Gutierrez M, Sarasa JL, Rey JA. Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. Am J Clin Pathol 2005;123:900-6.
22. Entz-Werle N, Vezuli A, Marec-Berard P, Dijoud F, De Muret A, Pasquier-Jeanne C, Guinebretierre M, Champigneulle M, Kalifa C, Brugiere L, Oudet P, Lutz P, et al. Microsatellite rearrangements of 4q12 locus and status of the candidate gene c-kit in pediatric osteosarcomas. Proc Am Assoc Cancer Res 2005;46 (abstract).
23. Lebuhn M, Effenberger M, Garces G, Gronauer A, Wilderer PA. Evaluating real-time PCR for the quantification of distinct pathogens and indicator organisms in environmental samples. Water Sci Technol 2004;50:263-70.
24. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:2011-18.
25. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20:426-33.
26. Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K. Activating mutations in c-KIT and PDGFRα are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005;11:1270-4.
27. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJM, Stoop J, Van Gurp RJMLH, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005;65:8085-9.
28. Gonzalez I, Andreu EJ, Panizo A, Inoges S, Fontalba A, Fernandez-Luna JL, Gaboli M, Sierrasesumaga L, Martin-Algarra S, Pardo J, Prosper F, De Alava E. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751-61.
29. All-Ericsson C, Girnita L, Müller-Brunotte A, Brodin B, Seregard S, Ostman A, Larsson O. c-kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophtalmol Vis Sci 2004;45:2075-82.
30. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002;100:585-93.
31. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
32. Decaudin D, De Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Freneaux P, Livartowski A, Pouillart P, Poupon MF. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 2005;113:849-56.
33. Mc Gary EW, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002;8:3584-91.
34. Man TK, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladnyi M, Gorlick R, Lau CC, Rao PH. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004;4:45.
35. Ozaki T, Neumann T, Wai D, Schafer KL, Van Valen F, Lindner N, Scheel C, Bocker W, Winkelmann W, Dockhorn-Dworniczak B, Horst J, Poremba C. Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping. Cancer Genet Cytogenet 2003;140:145-52.
36. Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S, Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003;16:66-71.
37. Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, Leverger G, Dosquet C. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 2001;7:538-43.